Towards Healthcare
Ankylosing Spondylitis Market Growth Drives USD 11.83 billion by 2035

Ankylosing Spondylitis Market Transformation Driven by Biologics & Biosimilars

Projections indicate that, the global ankylosing spondylitis market will increase from USD 6.7 billion in 2025 to USD 11.83 billion by 2035, experiencing a CAGR of 5.85% over the next 10 years. The rising prevalence of autoimmune disorders and growing research and development activities drive the global market. A robust healthcare infrastructure and favorable regulatory policies contribute to North America’s dominance. 

Content

  • Last Updated: 26 November 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

The ankylosing spondylitis market stands at USD 7.09 billion in 2026 and is expected to reach USD 11.83 billion by 2035, growing at a CAGR of 5.85% from 2026 to 2035.

North America is leading the ankylosing spondylitis market by 40% due to the availability of state-of-the-art research and development facilities, the presence of a robust healthcare infrastructure, and favorable regulatory support.

The ankylosing spondylitis market includes six segments by drug class, by route of administration, by disease stage, by diagnostic method, by end-user, and by region.

Some key players include Eli Lilly and Company, Sandoz Group AG, and Gilead Sciences.

Key trends include the rising prevalence of autoimmune disorders, advancements in biologics and diagnostic technologies, and increasing investments.

Some common symptoms of ankylosing spondylitis are back pain and stiffness, neck pain, fatigue, vision changes, skin rashes, stomach pain, and dyspnea.

Ankylosing spondylitis progresses through three stages early, progressive, and advanced. The early stage involves increasing pain and stiffness, while the advanced stage leads to bone fusion in the spine.
Any Questions